|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6B
|
|
pubmed:dateCreated |
1999-1-29
|
|
pubmed:abstractText |
In patients with gynecologic malignancies, a 6 kD polypeptide known as the tumor-associated trypsin inhibitor (TATI) is present in high concentrations, both in the urine and the serum. This study attempts to evaluate the usefulness of pretreatment serum levels of TATI (cutoff level 21 ng ml-1) and CA 125 (cutoff levels 35 U ml-1 and 65 U ml-1) in the prediction of early endometrial cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4635-9
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9891532-Adult,
pubmed-meshheading:9891532-Aged,
pubmed-meshheading:9891532-Aged, 80 and over,
pubmed-meshheading:9891532-CA-125 Antigen,
pubmed-meshheading:9891532-Endometrial Neoplasms,
pubmed-meshheading:9891532-Endometriosis,
pubmed-meshheading:9891532-Female,
pubmed-meshheading:9891532-Genital Diseases, Female,
pubmed-meshheading:9891532-Humans,
pubmed-meshheading:9891532-Middle Aged,
pubmed-meshheading:9891532-Neoplasm Staging,
pubmed-meshheading:9891532-Predictive Value of Tests,
pubmed-meshheading:9891532-Radioimmunoassay,
pubmed-meshheading:9891532-Reference Values,
pubmed-meshheading:9891532-Reproducibility of Results,
pubmed-meshheading:9891532-Sensitivity and Specificity,
pubmed-meshheading:9891532-Trypsin Inhibitor, Kazal Pancreatic,
pubmed-meshheading:9891532-Tumor Markers, Biological
|
|
pubmed:articleTitle |
TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
|
|
pubmed:affiliation |
Department of Gynecology and Obstetrics, Lainz Medical Center, Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article
|
